- A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-b, in patients with advanced nonsmall cell lung cancer (NSCLC)Feng, J.; Shi, M.; Chen, J.; Li, K.; Li, X.; Sun, M.; Li, B.; Wen, G.; Fang, Y.; Min, X.; Lin, L.; Liu, Y.; Wang, Q.; Lu, S.; Zhu, B.; Shi, Y-K.; Yu, H.; Peng, Y.; Liang, F.; Liu, P.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)Cheng, Y.; Qin, Z.; Meng, X.; Xu, F.; Wang, Y.; Yao, Y.; Fang, J.; Zhao, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/ TGF-bRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumorsXu, R-H.; Huiyan, L.; Zhao, H.; Wei, W.; Ma, D.; Yin, X.; Ni, Y.; Wang, Y.; Zhang, Y.; Zhou, J.; Pan, H.; Niu, Z.; Zhang, J.; Ren, H.; Kang, M.; Jia, W.; Gu, S.; Liu, P.; Zhang, Z.; Wang, S.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
会议论文
Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-?, in patients with advanced tumors
5被引30阅读
